Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals : Says NIH Study Found Its Tempol Drug Candidate to be Potential Antiviral For COVID-19

06/07/2021 | 08:46am EDT


ę MT Newswires 2021
All news about ADAMIS PHARMACEUTICALS CORPORATION
07/19ADAMIS PHARMACEUTICALS CORP : Submission of Matters to a Vote of Security Holder..
AQ
07/19ADAMIS PHARMACEUTICALS : Announces Results of 2021 Annual Meeting of Stockholder..
BU
07/19Declaration of Voting Results by Adamis Pharmaceuticals
CI
07/14ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Boa..
AQ
07/13Adamis Pharmaceuticals Solicits Proxies from Shareholders
CI
07/13ADAMIS PHARMACEUTICALS : Urges Stockholders to Vote to Reelect the Company's Boa..
BU
07/13ADAMIS PHARMACEUTICALS CORP : Regulation FD Disclosure, Financial Statements and..
AQ
07/02ADAMIS PHARMACEUTICALS : Sends Letter to Stockholders to Address Jerald A. Hamma..
AQ
07/01ADAMIS PHARMACEUTICALS : áAdamis Sends Letter to Stockholders to Address Jerald ..
BU
07/01Adamis Pharmaceuticals Solicits Proxies from Shareholders
CI
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,53x
Yield 2021 -
Capitalization 165 M 165 M -
Capi. / Sales 2021 7,51x
Capi. / Sales 2022 16,5x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,11 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
Robert O. Hopkins Chief Financial Officer & Secretary
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION128.82%165
JOHNSON & JOHNSON9.46%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.19.42%246 075
NOVARTIS AG0.14%225 528
ELI LILLY AND COMPANY46.06%224 166